Optimising HIV drug resistance testing laboratory networks in Kenya: insights from systems engineering modelling

被引:0
|
作者
Wang, Yinsheng [1 ]
Kingwara, Leonard [2 ]
Wagner, Anjuli Dawn [3 ]
Yongo, Nashon [4 ]
Hassan, Shukri A. [5 ]
Liu, Shan [6 ]
Oyaro, Patrick [7 ]
Patel, Rena C. [8 ,9 ]
机构
[1] Univ Washington, Dept Ind & Syst Engn, Seattle, WA 98195 USA
[2] Kenya Minist Hlth, Natl HIV Reference Lab, Nairobi, Kenya
[3] Univ Washington, Dept Global Hlth, Seattle, WA USA
[4] Univ Washington, Kenya Res & Training Ctr, Seattle, WA USA
[5] Univ Washington, Seattle, WA USA
[6] Univ Washington, Dept Ind & Syst Engn, Seattle, WA USA
[7] Hlth Innovat Kenya HIK, Kisumu, Kenya
[8] Univ Washington, Dept Med, Seattle, WA USA
[9] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA
来源
BMJ OPEN | 2024年 / 14卷 / 04期
关键词
HIV & AIDS; Decision Making; Health policy; POINT-OF-CARE; MIDDLE-INCOME COUNTRIES; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; 2ND-LINE TREATMENT; NON-INFERIORITY; OPEN-LABEL; DOLUTEGRAVIR; INFECTION; HEALTH;
D O I
10.1136/bmjopen-2023-079988
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background HIV drug resistance (DR) is a growing threat to the durability of current and future HIV treatment success. DR testing (DRT) technologies are very expensive and specialised, relying on centralised laboratories in most low and middle-income countries. Modelling for laboratory network with point-of-care (POC) DRT assays to minimise turnaround time (TAT), is urgently needed to meet the growing demand. Methods We developed a model with user-friendly interface using integer programming and queueing theory to improve the DRT system in Kisumu County, Kenya. We estimated DRT demand based on both current and idealised scenarios and evaluated a centralised laboratory-only network and an optimised POC DRT network. A one-way sensitivity analysis of key user inputs was conducted. Results In a centralised laboratory-only network, the mean TAT ranged from 8.52 to 8.55 working days, and the system could not handle a demand proportion exceeding 1.6%. In contrast, the mean TAT for POC DRT network ranged from 1.13 to 2.11 working days, with demand proportion up to 4.8%. Sensitivity analyses showed that expanding DRT hubs reduces mean TAT substantially while increasing the processing rate at national labs had minimal effect. For instance, doubling the current service rate at national labs reduced the mean TAT by only 0.0%-1.9% in various tested scenarios, whereas doubling the current service rate at DRT hubs reduced the mean TAT by 37.5%-49.8%. In addition, faster batching modes and transportation were important factors influencing the mean TAT. Conclusions Our model offers decision-makers an informed framework for improving the DRT system using POC in Kenya. POC DRT networks substantially reduce mean TAT and can handle a higher demand proportion than a centralised laboratory-only network, especially for children and pregnant women living with HIV, where there is an immediate push to use DRT results for patient case management.
引用
收藏
页数:11
相关论文
共 46 条
  • [1] HIV drug resistance: Insights from mathematical modelling
    Ngina, Purity
    Mbogo, Rachel Waema
    Luboobi, Livingstone S.
    [J]. APPLIED MATHEMATICAL MODELLING, 2019, 75 : 141 - 161
  • [2] Integration of HIV testing in tuberculosis drug resistance surveillance in Kazakhstan and Kenya
    Klinkenberg, E.
    van den Hof, S.
    Tursynbayeva, A.
    Kipruto, H.
    Wahogo, J.
    Pak, S.
    Kutwa, A.
    L'Herminez, R.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (05) : 615 - 617
  • [3] Implementation of a point mutation assay for HIV drug resistance testing in Kenya
    Duarte, Horacio A.
    Beck, Ingrid A.
    Levine, Molly
    Kiptinness, Catherine
    Kingoo, James M.
    Chohan, Bhavna
    Sakr, Samah R.
    Chung, Michael H.
    Frenkel, Lisa M.
    [J]. AIDS, 2018, 32 (16) : 2301 - 2308
  • [4] "I feel drug resistance testing allowed us to make an informed decision": qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya
    Scallon, Andrea J.
    Hassan, Shukri A.
    Qian, Shirley Rui
    Gao, Yuandi
    Oyaro, Patrick
    Brown, Evelyn
    Wagude, James
    Mukui, Irene
    Kinywa, Eunice
    Oluoch, Frederick
    Odhiambo, Francesca
    Oyaro, Boaz
    Kingwara, Leonard
    Yongo, Nashon
    Karauki, Enericah
    Otieno, Lindah
    John-Stewart, Grace C.
    Abuogi, Lisa L.
    Patel, Rena C.
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [5] “I feel drug resistance testing allowed us to make an informed decision”: qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya
    Andrea J. Scallon
    Shukri A. Hassan
    Shirley Rui Qian
    Yuandi Gao
    Patrick Oyaro
    Evelyn Brown
    James Wagude
    Irene Mukui
    Eunice Kinywa
    Frederick Oluoch
    Francesca Odhiambo
    Boaz Oyaro
    Leonard Kingwara
    Nashon Yongo
    Enericah Karauki
    Lindah Otieno
    Grace C. John-Stewart
    Lisa L. Abuogi
    Rena C. Patel
    [J]. BMC Health Services Research, 23
  • [6] HIV self-testing, PrEP, and drug resistance: some insights
    Ochieng, Walter
    Suraratdecha, Chutima
    [J]. LANCET HIV, 2024, 11 (03): : e134 - e136
  • [7] Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study
    Cox, Sarah N.
    Wu, Linxuan
    Wittenauer, Rachel
    Clark, Samantha
    Roberts, D. Allen
    Nwogu, Ifechukwu Benedict
    Vitruk, Olga
    Kuo, Alexandra P.
    Johnson, Cheryl
    Jamil, Muhammad S.
    Sands, Anita
    Schaefer, Robin
    Kisia, Christine
    Baggaley, Rachel
    Stekler, Joanne D.
    Akullian, Adam
    Sharma, Monisha
    [J]. LANCET HIV, 2024, 11 (03): : e167 - e175
  • [8] Validation of HIV-1 drug resistance testing by deep sequencing: insights from comparative Sanger sequencing
    Thielen, A.
    Martini, N.
    Thiele, B.
    Daeumer, M.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A78 - A78
  • [9] Validation of an HIV whole genome sequencing method for HIV drug resistance testing in an Australian clinical microbiology laboratory
    Jenkins, Frances
    Le, Thomas
    Farhat, Rima
    Pinto, Angie
    Anzari, Azim
    Bonsall, David
    Golubchik, Tanya
    Bowden, Rory
    Lee, Frederick J.
    van Hal, Sebastiaan J.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (12)
  • [10] Private sector HIV self-testing in Kenya: Insights from a Mystery shopper study
    Little, K.
    Odour, C.
    Awsumb, H.
    Essendi, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 13 - 13